Search the Newsreel

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts

Aquestive Therapeutics (NASDAQ:AQST) has received an average "Buy" rating from analysts, with a consensus 12-month price target of $8.50. Despite exceeding second-quarter revenue expectations, the company reported a larger-than-expected loss per share and issued full-year revenue guidance below analyst consensus. Insider selling and institutional …

Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission

Aquestive Therapeutics (AQST) stock experienced a 4% dip despite positive Q2 results showing increased liquidity and reaffirmed revenue guidance. The company is nearing resubmission of its Anaphylm New Drug Application, with management addressing FDA concerns. However, ongoing adjusted EBITDA losses and the dependence on …

Aquestive Therapeutics Releases Q2 2026 Financial Results

Aquestive Therapeutics (AQST) reported a Q2 2026 diluted loss per share of $0.18, exceeding the expected loss of $0.11, with total revenue reaching $13.8 million, a 38.0% increase year-over-year. The company's net loss for the quarter was $22.9 million, and it ended with $98.5 …

Aquestive Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AQST) 2026-08-12

Aquestive Therapeutics, Inc. (AQST) published its Q2 2026 earnings call presentation on August 12, 2026. The company reported an EPS of -$0.07, beating estimates by $0.05, and revenue of $13.82 million, a 38.15% year-over-year increase, beating estimates by $2.26 million. This presentation provides details …

Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Down Following Weak Earnings

Aquestive Therapeutics Q2 Earnings Call Highlights

Key Points Interested in Aquestive Therapeutics, Inc.? Here are five stocks we like better. Aquestive plans to resubmit Anaphylm's FDA application before the end of Q3 after revised packaging and instructions substantially reduced pouch-opening, film-tearing and administration errors in validation studies. Management is assuming …

Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026

Aquestive Therapeutics reported Q2 2026 revenue of $13.82 million, exceeding analyst estimates, but also posted a wider-than-expected loss of $0.18 per share due to an $11.7 million debt extinguishment charge. The company remains on track to resubmit its Anaphylm NDA to the FDA in …

Aquestive Therapeutics Q2 Loss Widens, Revenue Rises

Aquestive Therapeutics reported a wider net loss in Q2 compared to the previous year, despite an increase in total revenue. The company also updated its full-year 2026 outlook, anticipating total revenue to be between $58 million and $62 million, with non-GAAP adjusted EBITDA expected …

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.08 EPS

Aquestive Therapeutics: Q2 Earnings Snapshot

This article provides a brief "Q2 Earnings Snapshot" for Aquestive Therapeutics. It is a very short piece, indicating that the company's Q2 earnings were reported.

Aquestive Therapeutics (AQST) grows revenue and refinances debt in Q2 2026

Aquestive Plans to Take Epi Film Back to FDA with Positive Data

Aquestive Therapeutics plans to resubmit its drug application for Anaphylm, an oral dissolving film for severe allergic reactions, to the FDA this fall. This follows the completion of two additional studies requested by the FDA, which have yielded positive results regarding revised packaging, ease …

Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7.1% - Here's Why

Aquestive Therapeutics (NASDAQ:AQST) saw its shares rise 7.1% to $4.595, with a market capitalization of approximately $574 million. The company's stock holds a consensus "Buy" rating from analysts with an average price target of $8.50, driven by its recent beat on quarterly earnings expectations. …

Aquestive Therapeutics (AQST) Earnings Date and Reports 2026

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ sublingual film, an epinephrine product for severe allergic reactions. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in the third quarter of …

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics (AQST) announced positive results from human factors and pharmacokinetic validation studies for its Anaphylm sublingual film, a severe allergy treatment. These studies address prior FDA feedback, demonstrating significant improvements in product usability and effective drug delivery even with slight misplacement. The company …

Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Up - Should You Buy?

Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside

Aquestive Therapeutics Inc (AQST) is preparing to release its Q2 2026 earnings on August 11, 2026, with revenue expected at $11.42 million and earnings at $-0.12 per share. While analysts predict a significant upside of 125.61% based on average price targets, GuruFocus's GF Value …

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film

Aquestive Therapeutics has announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in Q3 2026, addressing previous issues with packaging and administration. …

Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials

Aquestive Therapeutics has released supplemental materials on human factors and clinical results for its Anaphylm (dibutepinephrine) sublingual film program. A resubmission human factors study showed fewer use issues compared to the original NDA study, with a median open time reduced to 3 seconds. A …

Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026

Aquestive announced positive human factors and pharmacokinetic (PK) results for Anaphylm, indicating significant improvements in usability and comparable drug delivery. These results support the planned New Drug Application (NDA) resubmission in Q3 2026 for the epinephrine treatment. The study showed reduced errors in self-administration …

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its officers. The lawsuit, filed on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, alleges that the company made false …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) who bought securities prior to June 16, 2025, and still hold them. The investigation aims to determine if Aquestive officers engaged in corporate wrongdoing. The firm …

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (NASDAQ:AQST) securities. The investigation focuses on whether Aquestive officers and/or directors engaged in corporate wrongdoing, particularly for investors who purchased shares before June 16, 2025, and still …

Earnings Preview: AQST to Report Financial Results Post-market on August 11

AQST is scheduled to announce its financial results after the market closes on August 11. Investors will be closely watching the earnings report for insights into the company's performance and future outlook. This preview serves as a heads-up for those tracking AQST's financial news.

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and certain officers. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval timeline for its drug Anaphylm, specifically related to human factors …

Aquestive Therapeutics (AQST) Expected to Announce Earnings on Tuesday

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (NASDAQ:AQST) for potential corporate wrongdoing. The firm encourages stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist in the investigation. The firm operates on a …

AQST|Aquestive Therapeutics Inc|Price:3.725|Chg%:+0.125

This article provides a comprehensive stock analysis of Aquestive Therapeutics Inc (AQST) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company has healthy fundamentals, high growth potential, and its valuation is considered fairly …

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics (NASDAQ: AQST) will release its second quarter 2026 financial results and provide business updates after market close on August 11, 2026. The company will then host a conference call for investors on August 12, 2026, at 8:00 a.m. ET to discuss these …

Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aquestive Therapeutics Inc (AQST), highlighting its current price momentum score, support and resistance levels, and indicator readings. It details various technical indicators like MACD, RSI, and moving averages, offering "Sell", "Neutral", and "Buy" signals. The analysis suggests …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to join the investigation. …